Belnacasan: meta-analysis of COVID-19 studies

All studies Recovery RCTs All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (1)−34%

RCTs (1)−34%

Early (1)−34%

00.511.5+

← Belnacasan
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

October 2026

Belnacasan COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wortmann (DB RCT)−34%1.34 · 0.78–2.29recov. time14 (n)17 (n)

Early treatment−34%1.34 · 0.78–2.2914 (n)17 (n)34% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−34%1.34 · 0.78–2.2914 (n)17 (n)34% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← Belnacasan
reduces riskBelnacasan
increases risk →

October 2026

Belnacasan COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wortmann (DB RCT)−34%1.34 · 0.78–2.29recov. time14 (n)17 (n)

Early treatment−34%1.34 · 0.78–2.2914 (n)17 (n)34% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−34%1.34 · 0.78–2.2914 (n)17 (n)34% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← Belnacasan
reduces riskBelnacasan
increases risk →

October 2026

Belnacasan COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wortmann (DB RCT)−34%1.34 · 0.78–2.29recov. time14 (n)17 (n)

Early treatment−34%1.34 · 0.78–2.2914 (n)17 (n)34% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.29

All studies−34%1.34 · 0.78–2.2914 (n)17 (n)34% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.2900.511.52+

Rotate screen for more detailsIncrease width for more details

← Belnacasan
reduces riskBelnacasan
increases risk →

October 2026

Belnacasan COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Wortmann (DB RCT)−34%1.34 · 0.78–2.29recov. time14 (n)17 (n) Wortmann (DB RCT)−43%1.43 · 0.99–2.06recov. time17 (n)17 (n) Wortmann (DB RCT)−31%1.31 · 0.71–2.41recov. time15 (n)8 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Belnacasan
reduces riskBelnacasan
increases risk →